Search results
Pfizer, Flagship name first target for multibillion-dollar collaboration: obesity
FierceBiotech· 4 days agoPfizer and Flagship Pioneering have settled on the first target for their billion-dollar,...
Bridgeway Capital Management LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 3 days agoBridgeway Capital Management LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 26.0% during the 4th quarter, according to its most recent 13F filing ...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with...
Morningstar· 4 days agoPfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin ...
Pfizer faces setback with gene therapy acquired from North Carolina firm - Triangle Business Journal
The Business Journals· 3 days agoPfizer is facing a major clinical setback in a gene therapy program with ties to the Triangle. The...
Pfizer’s Phase III DMD gene therapy trial misses primary endpoint
Clinical Trials Arena via Yahoo Finance· 3 days agoPfizer has reported that its Phase III CIFFREO clinical trial of investigational mini-dystrophin...
Sun Pharma Prevails in Lipitor MDL on Class Certification, Summary Judgment | New Jersey Law Journal
Law.com· 5 days agoA group of Lipitor purchasers that included retailers, wholesalers, health insurance companies, and...
UPDATE: Pfizer's phase 3 gene therapy trial fails to improve function for boys with Duchenne...
FierceBiotech· 4 days agoPfizer’s phase 3 gene therapy trial has failed to demonstrate significant improvement in motor...
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade |...
The Motley Fool· 18 hours agoThe S&P 500 is up an incredible 25% over the past 12 months, but not every stock in the benchmark...
Sarepta Jumps After Rival Gene Therapy From Pfizer Flops
Investor's Business Daily· 3 days agoThe news gives Sarepta Therapeutics (SRPT) an edge heading to June 21, when the Food and Drug Administration will decide whether to fully approve Elevidys for patients with the muscle-wasting ...
Pfizer's Duchenne gene therapy fails in late-stage study
Reuters· 4 days agoThe therapy also did not show a significant difference compared to placebo in secondary goals of the...